NKGen Biotech(NKGN)

Search documents
NKGen Biotech(NKGN) - 2023 Q2 - Quarterly Report
2023-08-14 21:06
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to GRAF ACQUISITION CORP. IV (Exact name of registrant as specified in its charter) Delaware 001-40427 86-2191918 (State or other jurisdictio ...
NKGen Biotech(NKGN) - 2023 Q1 - Quarterly Report
2023-05-15 20:11
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to GRAF ACQUISITION CORP. IV (Exact name of registrant as specified in its charter) Delaware 001-40427 86-2191918 (State or other jurisdicti ...
NKGen Biotech(NKGN) - 2022 Q4 - Annual Report
2023-03-31 21:10
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to GRAF ACQUISITION CORP. IV (Exact name of registrant as specified in its charter) | Delaware | 001-40427 | 86-2191918 | | --- | --- | --- | | | (C ...
NKGen Biotech(NKGN) - 2022 Q3 - Quarterly Report
2022-11-14 14:13
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to GRAF ACQUISITION CORP. IV (Exact name of registrant as specified in its charter) Delaware 001-40427 86-2191918 (State or other jurisd ...
NKGen Biotech(NKGN) - 2022 Q2 - Quarterly Report
2022-08-15 20:50
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to GRAF ACQUISITION CORP. IV (Exact name of registrant as specified in its charter) | Delaware | 001-40427 | 86-2191918 | | --- | --- | --- | ...
NKGen Biotech(NKGN) - 2022 Q1 - Quarterly Report
2022-05-16 20:10
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to GRAF ACQUISITION CORP. IV (Exact name of registrant as specified in its charter) | Delaware | 001-40427 | 86-2191918 | | --- | --- | --- ...
NKGen Biotech(NKGN) - 2021 Q4 - Annual Report
2022-03-31 01:27
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to GRAF ACQUISITION CORP. IV (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) ( ...
NKGen Biotech(NKGN) - 2021 Q3 - Quarterly Report
2021-11-15 21:13
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to GRAF ACQUISITION CORP. IV (Exact name of registrant as specified in its charter) | Delaware | 001-40427 | 86-2191918 | | --- | --- | ...
NKGen Biotech(NKGN) - 2021 Q2 - Quarterly Report
2021-08-16 20:55
(Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to GRAF ACQUISITION CORP. IV (Exact name of registrant as specified in its charter) Delaware 001-40427 86-2191918 (State or other jurisdiction of incorporation or organization) (Commission File Number) (I.R.S. Employer Identification Number) ...
NKGen Biotech(NKGN) - 2021 Q1 - Quarterly Report
2021-07-02 20:11
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to GRAF ACQUISITION CORP. IV (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organiz ...